161 related articles for article (PubMed ID: 38068988)
1. Zn
Sobczak AIS; Ajjan RA; Stewart AJ
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38068988
[TBL] [Abstract][Full Text] [Related]
2. Neutralisation of the anti-coagulant effects of heparin by histones in blood plasma and purified systems.
Longstaff C; Hogwood J; Gray E; Komorowicz E; Varjú I; Varga Z; Kolev K
Thromb Haemost; 2016 Mar; 115(3):591-9. PubMed ID: 26632486
[TBL] [Abstract][Full Text] [Related]
3. Influence of zinc on glycosaminoglycan neutralisation during coagulation.
Sobczak AIS; Pitt SJ; Stewart AJ
Metallomics; 2018 Sep; 10(9):1180-1190. PubMed ID: 30132486
[TBL] [Abstract][Full Text] [Related]
4. Zinc as a cofactor for heparin neutralization by histidine-rich glycoprotein.
Kluszynski BA; Kim C; Faulk WP
J Biol Chem; 1997 May; 272(21):13541-7. PubMed ID: 9153200
[TBL] [Abstract][Full Text] [Related]
5. Histidine-rich glycoprotein binds fibrin(ogen) with high affinity and competes with thrombin for binding to the gamma'-chain.
Vu TT; Stafford AR; Leslie BA; Kim PY; Fredenburgh JC; Weitz JI
J Biol Chem; 2011 Sep; 286(35):30314-30323. PubMed ID: 21757718
[TBL] [Abstract][Full Text] [Related]
6. Plasma free fatty acid levels influence Zn(2+) -dependent histidine-rich glycoprotein-heparin interactions via an allosteric switch on serum albumin.
Kassaar O; Schwarz-Linek U; Blindauer CA; Stewart AJ
J Thromb Haemost; 2015 Jan; 13(1):101-10. PubMed ID: 25353308
[TBL] [Abstract][Full Text] [Related]
7. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
Cosmi B; Fredenburgh JC; Rischke J; Hirsh J; Young E; Weitz JI
Circulation; 1997 Jan; 95(1):118-24. PubMed ID: 8994426
[TBL] [Abstract][Full Text] [Related]
8. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins.
Bendayan P; Boccalon H; Dupouy D; Boneu B
Thromb Haemost; 1994 May; 71(5):576-80. PubMed ID: 8091383
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4).
Padilla A; Gray E; Pepper DS; Barrowcliffe TW
Br J Haematol; 1992 Oct; 82(2):406-13. PubMed ID: 1329921
[TBL] [Abstract][Full Text] [Related]
10. A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation.
Volovyk Z; Monroe DM; Qi Y; Becker R; Hoffman M
J Thromb Thrombolysis; 2009 Aug; 28(2):132-9. PubMed ID: 19543696
[TBL] [Abstract][Full Text] [Related]
11. Zn2+ mediates high affinity binding of heparin to the αC domain of fibrinogen.
Fredenburgh JC; Leslie BA; Stafford AR; Lim T; Chan HH; Weitz JI
J Biol Chem; 2013 Oct; 288(41):29394-402. PubMed ID: 23990470
[TBL] [Abstract][Full Text] [Related]
12. Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation.
Kitazato K; Kitazato KT; Sasaki E; Minamiguchi K; Nagase H
Thromb Res; 2003; 112(1-2):83-91. PubMed ID: 15013278
[TBL] [Abstract][Full Text] [Related]
13. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
Pindur G; Heiden M; Köhler M
Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
[TBL] [Abstract][Full Text] [Related]
14. Involvement of the extrinsic pathway in the activities of low molecular weight heparins.
Norrheim L; Abildgaard U; Larsen ML; Lindahl AK
Thromb Res Suppl; 1991; 14():19-27. PubMed ID: 1658967
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
[TBL] [Abstract][Full Text] [Related]
16. Histidine-rich glycoprotein binds to cell-surface heparan sulfate via its N-terminal domain following Zn2+ chelation.
Jones AL; Hulett MD; Parish CR
J Biol Chem; 2004 Jul; 279(29):30114-22. PubMed ID: 15138272
[TBL] [Abstract][Full Text] [Related]
17. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
[TBL] [Abstract][Full Text] [Related]
18. Histidine-rich glycoprotein plus zinc to neutralize heparin.
Fu CL; Horn MK
J Lab Clin Med; 2002 Apr; 139(4):211-7. PubMed ID: 12024108
[TBL] [Abstract][Full Text] [Related]
19. Relationship between ex vivo anti-proteinase (factor Xa and thrombin) assays and in vivo anticoagulant effect of very low molecular weight heparin, CY222.
Tew CJ; Lane DA; Thompson E; Ireland H; Curtis JR
Br J Haematol; 1988 Nov; 70(3):335-40. PubMed ID: 2849981
[TBL] [Abstract][Full Text] [Related]
20. Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability.
van de Berg TW; Hulshof AM; Nagy M; van Oerle R; Sels JW; van Bussel B; Ten Cate H; Henskens Y; Spronk HMH;
Thromb Res; 2021 May; 201():84-89. PubMed ID: 33662799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
